NewsBenzingaReported Sunday, Vir’s Elebsiran And Tobevibart Meet Primary Endpoint In Phase 3 ECLIPSE 1 Hepatitis Delta Trial, 44% Achieve Undetectable Virus Plus ALT Normalization Versus 0% Delayed Treatment Reported Sunday, Vir’s Elebsiran And Tobevibart Meet Primary Endpoint In Phase 3 ECLIPSE 1 Hepatitis Delta Trial, 44% Achieve Undetectable Virus Plus ALT Normalization Versus 0% Delayed Treatment Benzinga 2026.11.09 07:49 (GMT+0) Open on Benzinga Other news Abraxas Capital Moves $109 Million USDC to Binance After Closing Its ~$200 Million Hyperliquid Positions Ledger Hardware Wallet Tampering Spreads to Dubai as Two Users Lose About $604K Nvidia Board Has No Plans to Reinstate Jensen Huang AMD completes acquisition of AI inference chip company Taalas HUYA Inc. (HUYA) Q3 2026 Earnings Call Transcript Key Overnight and Morning News (Nov 17 – Nov 18)
Abraxas Capital Moves $109 Million USDC to Binance After Closing Its ~$200 Million Hyperliquid Positions